Related Experiment Videos
Apoptin
1Department of Molecular Cell Biology, Leiden University Medical Center, The Netherlands.
Abstract:
Tumor cells are often characterized by the traithey are more resistant to apoptosis induced by e.g. cytotoxic agents than normal cells. Resistance to apoptosis induction can be a direct consequence of mutations in certain tumor-suppressor genes (p53) or of certain proto-oncogenes (Bcl-2). Therefore, new cancer therapies are under development to bypass the resistance to chemo- and radio-therapy of tumors. Apoptin acts independently of p53, is stimulated by Bcl-2 and is insensitive to BCR-ABL, which means that Apoptin can induce apoptosis in cases where present (chemo)-therapeutic agents, unfortunately, will fail. The fact that Apoptin induces apoptosis in human tumorigenic cells but not in normal diploid cells, implies that side-effects of Apoptin treatment are expected to be minor. In-vivo results with a first prototype of anti-tumor therapy based on expression of Apoptin indicate that Apoptin has low acute toxicity and is effective as an anti-tumor agent.
Insights
Apoptin effectively induces apoptosis in tumor cells resistant to conventional therapies, offering a promising new cancer treatment with minimal side effects. This novel agent bypasses common resistance mechanisms, showing potential for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Tumor cells exhibit resistance to apoptosis, a key challenge in cancer therapy.
- This resistance is often linked to mutations in tumor suppressors like p53 or oncogenes such as Bcl-2.
- Existing therapies face limitations due to tumor resistance mechanisms.
Purpose of the Study:
- To investigate Apoptin as a novel anti-cancer agent.
- To evaluate Apoptin's efficacy in inducing apoptosis in resistant tumor cells.
- To assess Apoptin's safety profile and potential for targeted cancer therapy.
Main Methods:
- Apoptin's mechanism of action was studied in relation to p53, Bcl-2, and BCR-ABL.
- Apoptosis induction was assessed in human tumorigenic and normal diploid cells.
- In-vivo studies were conducted using a prototype Apoptin-based anti-tumor therapy.
Main Results:
- Apoptin induces apoptosis independently of p53 and is stimulated by Bcl-2.
- Apoptin is insensitive to BCR-ABL, overcoming specific resistance pathways.
- Apoptin selectively targets human tumorigenic cells, sparing normal cells.
- In-vivo studies demonstrated low acute toxicity and significant anti-tumor efficacy.
Conclusions:
- Apoptin represents a novel therapeutic strategy for overcoming chemo- and radio-therapy resistance in tumors.
- Its selective action on cancer cells suggests a favorable safety profile with potentially minor side effects.
- Apoptin shows promise as an effective and well-tolerated anti-cancer agent.